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DIFFERENCE-IN-DIFFERENCES ANALYSIS OF THE IMPACT OF ORAL ANTICOAGULANT 
PRESCRIBING ON INCIDENCE OF ATRIAL-FIBRILLATION-RELATED STROKE  
Orlowski A1, Jianhua Wu2, Julia Wilkins1, Wayne Smith1 
1Imperial College Health Partners, London, UK, 2University of Leeds, Leeds, UK 
OBJECTIVES: Assess whether the change in the rates of use of direct oral anticoagulants 
(DOACs) and warfarin has a relation atrial fibrillation (AF)-related stroke incidence. 
METHODS: Data on AF-related stroke cases (stroke as primary diagnosis, AF as secondary 
diagnosis) were obtained from Hospital Episode Statistics data (copyright NHS Digital 2018), 
prescribing data from the electronic Prescribing and Costing Tool, and AF detection and 
treatment data from the Quality and Outcomes Framework data. A difference-in-differences (DiD) 
analysis was performed with Poisson regression to compare the impact of DOAC use on stroke 
incidence in 2011±2013 versus 2015±2017, across all clinical commissioning groups (CCGs) in 
England and adjusted for AF prevalence. RESULTS: When the CCGs were ranked from low to 
high by the number of strokes, the number of DOAC prescriptions increased accordingly, but this 
change was probably due the size of the CCG population. A trend was seen towards a reduction 
in adjusted AF-related stroke incidence in relation to increased oral anticoagulant prescribing 
across England. Despite not reaching significance overall, within CCGs that used more DOACs 
than warfarin reductions were significant for all stroke (risk ratio 0.97, 95% CI 0.95±0.98) and 
ischaemic stroke (risk ratio 0.96, 95% CI 0.94±0.98). CONCLUSIONS: DOAC prescribing rose 
substantially throughout England in the period 2011±2017. This DiD analysis demonstrates that 
although the efficacy of DOACs and warfarin for the prevention of stroke are considered to be 
similar, the higher clinical use of DOACs appears to offer better patient outcomes in the real-
world setting. Given the ageing population, which is likely to lead to an increase in AF, and 
thereby stroke, further analysis seems warranted to investigate the potential for improved 
benefits from increased DOAC prescribing at the population level in the real-world clinical setting. 
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